These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 33993822)

  • 1. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy.
    Ascoli M; Mastroianni G; Gasparini S; Striano P; Cianci V; Neri S; Bova V; Mammì A; Gambardella A; Labate A; Aguglia U; Ferlazzo E
    Expert Rev Neurother; 2021 Nov; 21(11):1265-1273. PubMed ID: 33993822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.
    Milano C; Turco F; Pizzanelli C; Bonanni E; Siciliano G; Fornai F; Giorgi FS
    Epilepsy Behav; 2021 Feb; 115():107706. PubMed ID: 33423017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020.
    Kılıç B; Serdaroğlu E; Polat BG; İnce T; Esenülkü G; Topçu Y; Serdaroğlu A; Haspolat Ş; Tekgül H; Okuyaz Ç; Cansu A; Aydın K
    Seizure; 2022 Jul; 99():48-53. PubMed ID: 35594744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy.
    Sala-Padró J; Toledo M; Santamarina E; González-Cuevas M; Raspall-Chaure M; Sueiras-Gil M; Quintana M; Salas-Puig X
    Clin Neuropharmacol; 2016; 39(6):299-301. PubMed ID: 27438183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.
    Tabrizi N; Zarvani A; Rezaei P; Cheraghmakani H; Alizadeh-Navaei R
    Epilepsy Res; 2019 Nov; 157():106214. PubMed ID: 31627041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy.
    Johannessen Landmark C; Fløgstad I; Syvertsen M; Baftiu A; Enger U; Koht J; Johannessen SI
    Epilepsy Behav; 2019 Sep; 98(Pt A):110-116. PubMed ID: 31330379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-naïve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures.
    Abdelmesih SK; Elkhateeb N; Zakaria M; Girgis MY
    Seizure; 2021 Oct; 91():263-270. PubMed ID: 34246881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
    Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
    Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy.
    Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI
    Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME).
    Asadi-Pooya AA; Hashemzehi Z; Emami M
    Seizure; 2014 Nov; 23(10):889-91. PubMed ID: 25189101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.
    Serafini A; Gerard E; Genton P; Crespel A; Gelisse P
    CNS Drugs; 2019 Mar; 33(3):195-208. PubMed ID: 30747367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
    Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
    Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road.
    Baheti N; Rathore C; Bansal AR; Shah S; Veedu HK; Prakash S; Kanhere K; Jaiswal SK; Jukkarwala A; Murthy JMK; Radhakrishnan K
    Seizure; 2021 Nov; 92():112-117. PubMed ID: 34496330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
    Chowdhury A; Brodie MJ
    Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electroclinical aspects and therapy of Han patients with juvenile myoclonic epilepsy in northern China.
    Wang L; Jiang Z; Chen BB; Wang CT; Wang JX; Bai J; Wang B; Jin L; Zhang WJ; Deng YC; Zhao G; Dang JX; Wang D; Jia SS; Wang TC; Jia FY; Zhang L; Liu YH
    Epilepsy Behav; 2016 Sep; 62():204-8. PubMed ID: 27494356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.
    Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE
    Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Juvenile myoclonic epilepsy].
    Syvertsen MR; Markhus R; Selmer KK; Nakken KO
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1610-3. PubMed ID: 22875125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
    Montouris G; Abou-Khalil B
    Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Juvenile myoclonic epilepsy with recurrent myoclonic status: efficacy of valproate].
    Crespel A; Velizarova R; Genton P; Gélisse P
    Therapie; 2009; 64(5):321-3. PubMed ID: 19863907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of juvenile myoclonic epilepsy.
    Auvin S
    CNS Neurosci Ther; 2008; 14(3):227-33. PubMed ID: 18684236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.